PUBLICATIONS AND PresentationS
Discover the main highlights of our industry in our latest publications.






Quick links
Presentation
Publication
Key Economic & Value Considerations in the US
Market for PPTs
Market for PPTs
Key Economic & Value Considerations for PDMPs
in Europe
in Europe
Plasma donation: New thinking to serve Europe’s patients -- Practices & approaches for countries
Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Dec 1, 2024
Adverse Events Among U.S. Source Plasma Donors – Plasmavigilance II
As a follow up to the 2021 PPTA study, “Plasmavigilance – Adverse Events Among U.S. Source Plasma [SP] Donors,” published in Transfusion, PPTA analyzed hypotensive adverse events (HAE) rates and SP donor characteristics that may be predictors of a HAE.
All
Publication
https://drive.google.com/file/d/1gAF8US04_IE6h0a3-ERhGlWTV91xGa82/view
Dec 1, 2024
Adverse Events Among U.S. Source Plasma Donors – Plasmavigilance II
As a follow up to the 2021 PPTA study, “Plasmavigilance – Adverse Events Among U.S. Source Plasma [SP] Donors,” published in Transfusion, PPTA analyzed hypotensive adverse events (HAE) rates and SP donor characteristics that may be predictors of a HAE.
All
Publication
https://drive.google.com/file/d/1gAF8US04_IE6h0a3-ERhGlWTV91xGa82/view
Nov 19, 2024
Consistent supply of global plasma for global patients
All
Publication
https://onlinelibrary.wiley.com/doi/10.1111/vox.13771
Nov 19, 2024
Consistent supply of global plasma for global patients
All
Publication
https://onlinelibrary.wiley.com/doi/10.1111/vox.13771
Apr 25, 2024
Hypotensive adverse events among U.S. source plasma donors: Plasmavigilance II
All
Publication
https://onlinelibrary.wiley.com/doi/epdf/10.1111/vox.13652
Apr 25, 2024
Hypotensive adverse events among U.S. source plasma donors: Plasmavigilance II
All
Publication
https://onlinelibrary.wiley.com/doi/epdf/10.1111/vox.13652
No results found

